 Source: Rob Byron Shutterstock.com Aquestive Therapeutics NASDAQ: AQST stock is taking off on Tuesday as investors react to positive clinical trial data from the pharmaceutical company. Aquestive Therapeutics is developing a rival to EpiPen and the results from its Phase 2 clinical trial are in. 